A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment
Фаза 2
Прекращено
NCT04933695
| Заболевание | Non-small Cell Lung Cancer |
|---|
| Фаза | Фаза 2 |
|---|
| Спонсор | Amgen |
|---|
| Статус | Прекращено |
|---|
| Участники | 42 участн. |
|---|
| Вмешательство | Sotorasib |
|---|
| Дата начала | 28.01.2022 |
|---|
| Дата завершения | 28.05.2025 |
|---|
| Публикация результатов | 13.07.2026 |
|---|
Кратко
The main objective of this study is to evaluate the tumor objective response rate (ORR) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria in participants who receive sotorasib at either 960 mg daily or 240 mg daily whose tumors are programmed death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) \< 1% and/or harbor a serine/threonine kinase 11 (STK11) co-mutation, in a subgroup of participants with PD-L1 \< 1% and in a subgroup of participants with STK11 co-mutation.
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)
From the first dose of trial drug until min (last dose + 30 days, end of trial [EOT]); median [min, max] duration was 5.32 [0.8, 30.9] months · percentage of participants
| Sotorasib | 26.8 percentage of participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.